TSE:AKU

Akumin Competitors

C$4.67

0.00 (0.00 %)

(As of 03/2/2021 12:00 AM ET)

Add

Compare

Today's Range

C$4.62

Now: C$4.67▼

C$4.70

50-Day Range

C$3.72

MA: C$4.11▼

C$4.70

52-Week Range

C$1.75

Now: C$4.67▼

C$4.98

Volume11,400 shs

Average Volume61,718 shs

Market CapitalizationC$326.16 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Akumin (TSE:AKU) Vs. LXG, SQD, SVA, GEN, LMD, and VPT

Should you be buying AKU stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to Akumin, including LexaGene (LXG), SQI Diagnostics Inc. (SQD.V) (SQD), Sernova Corp. (SVA.V) (SVA), GeneNews (GEN), LED Medical Diagnostics (LMD), and VentriPoint Diagnostics Ltd. (VPT.V) (VPT).

Akumin vs. LexaGene Stock

LexaGene (CVE:LXG) and Akumin (TSE:AKU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.

Valuation & Earnings

This table compares LexaGene and Akumin's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LexaGene	N/A	N/A	N/A	C($0.10)	-11.58
Akumin	C$269.04 million	1.21	C$-1,396,820.00	C($0.02)	-233.50

LexaGene has higher earnings, but lower revenue than Akumin. Akumin is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for LexaGene and Akumin, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LexaGene	0	0	0	0	N/A
Akumin	0	1	1	0	2.50

Akumin has a consensus target price of C$4.25, indicating a potential downside of 8.99%. Given Akumin's higher possible upside, analysts plainly believe Akumin is more favorable than LexaGene.

Profitability

This table compares LexaGene and Akumin's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LexaGene	N/A	N/A	N/A
Akumin	N/A	N/A	N/A

Summary

Akumin beats LexaGene on 4 of the 5 factors compared between the two stocks.

Akumin vs. SQI Diagnostics Inc. (SQD.V) Stock

SQI Diagnostics Inc. (SQD.V) (CVE:SQD) and Akumin (TSE:AKU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.

Valuation & Earnings

This table compares SQI Diagnostics Inc. (SQD.V) and Akumin's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SQI Diagnostics Inc. (SQD.V)	C$1.02 million	125.51	C$-10,402,144.00	C($0.03)	-12.34
Akumin	C$269.04 million	1.21	C$-1,396,820.00	C($0.02)	-233.50

Akumin has higher revenue and earnings than SQI Diagnostics Inc. (SQD.V). Akumin is trading at a lower price-to-earnings ratio than SQI Diagnostics Inc. (SQD.V), indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for SQI Diagnostics Inc. (SQD.V) and Akumin, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SQI Diagnostics Inc. (SQD.V)	0	0	0	0	N/A
Akumin	0	1	1	0	2.50

Akumin has a consensus target price of C$4.25, indicating a potential downside of 8.99%. Given Akumin's higher possible upside, analysts plainly believe Akumin is more favorable than SQI Diagnostics Inc. (SQD.V).

Profitability

This table compares SQI Diagnostics Inc. (SQD.V) and Akumin's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SQI Diagnostics Inc. (SQD.V)	N/A	N/A	N/A
Akumin	N/A	N/A	N/A

Summary

Akumin beats SQI Diagnostics Inc. (SQD.V) on 5 of the 7 factors compared between the two stocks.

Akumin vs. Sernova Corp. (SVA.V) Stock

Sernova Corp. (SVA.V) (CVE:SVA) and Akumin (TSE:AKU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.

Valuation & Earnings

This table compares Sernova Corp. (SVA.V) and Akumin's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sernova Corp. (SVA.V)	N/A	N/A	N/A	C($0.03)	-52.96
Akumin	C$269.04 million	1.21	C$-1,396,820.00	C($0.02)	-233.50

Sernova Corp. (SVA.V) has higher earnings, but lower revenue than Akumin. Akumin is trading at a lower price-to-earnings ratio than Sernova Corp. (SVA.V), indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Sernova Corp. (SVA.V) and Akumin, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sernova Corp. (SVA.V)	0	0	0	0	N/A
Akumin	0	1	1	0	2.50

Profitability

This table compares Sernova Corp. (SVA.V) and Akumin's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sernova Corp. (SVA.V)	N/A	N/A	N/A
Akumin	N/A	N/A	N/A

Summary

Akumin beats Sernova Corp. (SVA.V) on 4 of the 5 factors compared between the two stocks.

Akumin vs. GeneNews Stock

GeneNews (TSE:GEN) and Akumin (TSE:AKU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.

Valuation & Earnings

This table compares GeneNews and Akumin's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneNews	C$234,592.00	0.00	C$-11,557,484.00	C($0.07)	N/A
Akumin	C$269.04 million	1.21	C$-1,396,820.00	C($0.02)	-233.50

Akumin has higher revenue and earnings than GeneNews. Akumin is trading at a lower price-to-earnings ratio than GeneNews, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for GeneNews and Akumin, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneNews	0	0	0	0	N/A
Akumin	0	1	1	0	2.50

Akumin has a consensus target price of C$4.25, indicating a potential downside of 8.99%.

Profitability

This table compares GeneNews and Akumin's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeneNews	N/A	N/A	N/A
Akumin	N/A	N/A	N/A

Summary

Akumin beats GeneNews on 4 of the 5 factors compared between the two stocks.

Akumin vs. LED Medical Diagnostics Stock

LED Medical Diagnostics (CVE:LMD) and Akumin (TSE:AKU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.

Profitability

This table compares LED Medical Diagnostics and Akumin's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LED Medical Diagnostics	N/A	N/A	N/A
Akumin	N/A	N/A	N/A

Valuation & Earnings

This table compares LED Medical Diagnostics and Akumin's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LED Medical Diagnostics	C$14.96 million	1.04	C$-1,512,615.00	C($0.04)	-10.26
Akumin	C$269.04 million	1.21	C$-1,396,820.00	C($0.02)	-233.50

Akumin has higher revenue and earnings than LED Medical Diagnostics. Akumin is trading at a lower price-to-earnings ratio than LED Medical Diagnostics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for LED Medical Diagnostics and Akumin, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LED Medical Diagnostics	0	0	0	0	N/A
Akumin	0	1	1	0	2.50

Summary

Akumin beats LED Medical Diagnostics on 6 of the 7 factors compared between the two stocks.

Akumin vs. VentriPoint Diagnostics Ltd. (VPT.V) Stock

VentriPoint Diagnostics Ltd. (VPT.V) (CVE:VPT) and Akumin (TSE:AKU) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Profitability

This table compares VentriPoint Diagnostics Ltd. (VPT.V) and Akumin's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VentriPoint Diagnostics Ltd. (VPT.V)	N/A	N/A	N/A
Akumin	N/A	N/A	N/A

Valuation and Earnings

This table compares VentriPoint Diagnostics Ltd. (VPT.V) and Akumin's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VentriPoint Diagnostics Ltd. (VPT.V)	C$37,517.00	1,483.81	C$-4,128,201.00	C($0.03)	-13.48
Akumin	C$269.04 million	1.21	C$-1,396,820.00	C($0.02)	-233.50

Akumin has higher revenue and earnings than VentriPoint Diagnostics Ltd. (VPT.V). Akumin is trading at a lower price-to-earnings ratio than VentriPoint Diagnostics Ltd. (VPT.V), indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for VentriPoint Diagnostics Ltd. (VPT.V) and Akumin, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VentriPoint Diagnostics Ltd. (VPT.V)	0	0	0	0	N/A
Akumin	0	1	1	0	2.50

Akumin has a consensus target price of C$4.25, suggesting a potential downside of 8.99%. Given Akumin's higher possible upside, analysts clearly believe Akumin is more favorable than VentriPoint Diagnostics Ltd. (VPT.V).

Summary

Akumin beats VentriPoint Diagnostics Ltd. (VPT.V) on 5 of the 7 factors compared between the two stocks.